• Users Online: 73
  • Print this page
  • Email this page


 
 
Table of Contents
CORRIGENDUM
Year : 2022  |  Volume : 5  |  Issue : 3  |  Page : 110-111

Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study


Date of Web Publication13-Oct-2022

Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/glioma.glioma_19_22

Rights and Permissions

How to cite this article:
. Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma 2022;5:110-1

How to cite this URL:
. Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma [serial online] 2022 [cited 2022 Nov 30];5:110-1. Available from: http://www.jglioma.com/text.asp?2022/5/3/110/358551



In the article titled “Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study,” published on pages 29-38, Issue 1, Volume 5 of Glioma,[1] [Figure 1] has been incorrectly published. The correct [Figure 1] is given below.
Figure 1: Schedule of enrollment, interventions, and assessments

Click here to view


The authors apologize for any inconvenience this correction may cause for readers and editors of Glioma.



 
  References Top

1.
Lin F, Guo C, Yang Q, Chen Y, Ke C, Sai K, et al. Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma 2022;5:29-38.  Back to cited text no. 1
  [Full text]  


    Figures

  [Figure 1]



 

Top
 
  Search
 
    Similar in PUBMED
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References
Article Figures

 Article Access Statistics
    Viewed250    
    Printed4    
    Emailed0    
    PDF Downloaded38    
    Comments [Add]    

Recommend this journal